Deborah Persaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/93820/publications.pdf

Version: 2024-02-01

36 papers 1,968 citations

430874 18 h-index 395702 33 g-index

37 all docs

 $\begin{array}{c} 37 \\ \text{docs citations} \end{array}$

37 times ranked

2004 citing authors

#	Article	IF	CITATIONS
1	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. Journal of Infectious Diseases, 2022, 225, 1741-1749.	4.0	35
2	Experience and Outcomes of Breastfed Infants of Women Living With HIV in the United States: Findings From a Single-Center Breastfeeding Support Initiative. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 24-27.	1.3	19
3	Assessing the Variability of Cell-Associated HIV DNA Quantification through a Multicenter Collaborative Study. Microbiology Spectrum, 2022, 10, .	3.0	2
4	Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase $1/2$ proof of concept study. Lancet HIV, the, 2021, 8, e149-e157.	4.7	12
5	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Journal of Infectious Diseases, 2021, 224, 1581-1592.	4.0	72
6	Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding. Journal of Infectious Diseases, 2021, 224, 606-615.	4.0	30
7	Clinical validation of a quantitative HIV-1 DNA droplet digital PCR assay: Applications for detecting occult HIV-1 infection and monitoring cell-associated HIV-1 dynamics across different subtypes in HIV-1 prevention and cure trials. Journal of Clinical Virology, 2021, 139, 104822.	3.1	11
8	Insights from Clonal Expansion and HIV Persistence in Perinatal Infections. MBio, 2021, 12, e0098321.	4.1	0
9	Quantitative HIV-1-specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA concentrations. Aids, 2020, 34, 1117-1126.	2.2	4
10	Capitalizing on Post-exposure ARV Prophylaxis to Restrict Seeding of the HIV Reservoir. Clinical Infectious Diseases, 2020, 73, 439-440.	5.8	2
11	Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure. Current HIV/AIDS Reports, 2020, 17, 237-248.	3.1	10
12	Differences in inducibility of the latent HIV reservoir in perinatal and adult infection. JCI Insight, 2020, 5, .	5.0	21
13	The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32â^'CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression. Journal of Infectious Diseases, 2019, 219, 80-88.	4.0	9
14	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	4.7	139
15	Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. Aids, 2019, 33, 211-218.	2.2	18
16	Quantitative HIV-1 antibodies correlate with plasma HIV-1 RNA and cell-associated DNA levels in children on ART. Clinical Infectious Diseases, 2018, 68, 1725-1732.	5.8	14
17	CNS Persistence of HIV-1 in Children: the Untapped Reservoir. Current HIV/AIDS Reports, 2018, 15, 382-387.	3.1	13
18	Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1–Infected Infants. Journal of Infectious Diseases, 2018, 218, 1085-1089.	4.0	13

#	Article	IF	CITATIONS
19	Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda. Pediatric Infectious Disease Journal, 2018, 37, e298-e303.	2.0	7
20	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study. Blood, 2018, 132, 2184-2184.	1.4	0
21	Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection. Clinical Infectious Diseases, 2017, 64, 1471-1478.	5.8	34
22	Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing. Journal of Infectious Diseases, 2017, 216, S834-S837.	4.0	6
23	Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection. PLoS ONE, 2017, 12, e0170548.	2.5	21
24	Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. Clinical Infectious Diseases, 2015, 61, 1862-1870.	5.8	49
25	Viremic Relapse after HIV-1 Remission in a Perinatally Infected Child. New England Journal of Medicine, 2015, 372, 786-788.	27.0	242
26	HIV Type 1 (HIV-1) Proviral Reservoirs Decay Continuously Under Sustained Virologic Control in HIV-1–Infected Children Who Received Early Treatment. Journal of Infectious Diseases, 2014, 210, 1529-1538.	4.0	123
27	Influence of Age at Virologic Control on Peripheral Blood Human Immunodeficiency Virus Reservoir Size and Serostatus in Perinatally Infected Adolescents. JAMA Pediatrics, 2014, 168, 1138.	6.2	85
28	Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. Journal of Virological Methods, 2014, 207, 182-187.	2.1	5
29	Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant. New England Journal of Medicine, 2013, 369, 1828-1835.	27.0	520
30	Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. Aids, 2012, 26, 1483-1490.	2.2	79
31	Slower Clearance of Nevirapine Resistant Virus in Infants Failing Extended Nevirapine Prophylaxis for Prevention of Mother-to-Child HIV Transmission. AIDS Research and Human Retroviruses, 2011, 27, 823-829.	1.1	28
32	Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. Aids, 2011, 25, 2227-2234.	2.2	30
33	Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor–Resistant HIVâ€1 among Recently Infected Infants Born in the United States. Journal of Infectious Diseases, 2007, 195, 1402-1410.	4.0	58
34	Latent HIV-1 reservoirs in children: considerations for therapy. Current Opinion in HIV and AIDS, 2006, 1, 174-8.	3.8	0
35	Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads. Journal of Virology, 2004, 78, 968-979.	3.4	98
36	Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers. Journal of Virology, 2003, 77, 1659-1665.	3.4	158